Non-small cell lung cancer. Survival after radiotherapy and prognostic factors;Carcinoma no microcítico de pulmón. Supervivencia y factores pronósticos del tratamiento radioterápico

Archivos de Bronconeumologia

Volumn 39, Issue 2, 2003, Pages 81-86

  Jaen Olasolo J ^a   Alonso Redondo, E ^a   Leon Jimenez A ^a   Rueda Ramos, A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Chemotherapy; Lung cancer; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; ESOPHAGUS DISEASE; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RADIATION DOSE; SKIN TOXICITY; TREATMENT OUTCOME; TUMOR VOLUME; ESOPHAGUS; LARYNX; LIFE TABLE; LUNG TUMOR; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION INJURY; RADIOTHERAPY; SPAIN; STOMACH; SURVIVAL; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; ESOPHAGUS; HUMANS; LARYNX; LIFE TABLES; LUNG NEOPLASMS; LYMPHATIC IRRADIATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIATION INJURIES; RADIODERMATITIS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SPAIN; STOMACH; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0042787531     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13043588     Document Type: Article

References (42)

1. López-Albente G, Pollan M, De la Iglesia P, Ruiz M. Characterization of the lung cancer epidemic in the European Union (1970-1990). Cancer Epidermiol Biomarkers Prev 1995;4:813-20.
2. Bonfill X, Moreno C, Prada G, Rivero E, Rue M. Lung cancer mortality among males of Catalonia and Spain compared with other European countries between 1975-77 and 1987-89. Int J Cancer 1996;65:751-4.
3. American Cancer Society. Cancer facts & figures - 1997. Atlanta: American Cancer Society, 1997.
4. Humphrey EW, Smart CR, Winchester DP, et al. National survey of the pattern of care for carcinoma of the lung. J Thorac Cardiovasc Surg 1990;100:837-43.
5. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999;52:137-48.
6. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomised clinical trials. Int J Radiat Oncol Biol Phys 1997;37:259-67.
7. Liao Z, Komaki R, Stevens C, Kelly J, Fossella F, Lee JS, et al. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;53:558-65.
8. Non-small cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
9. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995;76:593-601.
10. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996;125:723-9.
11. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
12. th ed. Philadelphia: Lippincott-Raven Publishers, 1997; p. 127-37.
13. Grupo de Trabajo de la SEPAR. Normativa actualizada (1998) sobre diagnóstico y estadificación del carcinoma broncogénico. Arch Bronconeumol 1998;34:437-52.
14. Karnofsky DA, Buchenal JH. Clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949; p. 191-205.
15. Zubrod CG, Schneiderman M, Frei E. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960;11:7-33.
16. Cordiner A, De Carlo F, De Gennaro R, et al. Prediction of postoperative pulmonary function following thoracic surgery for bronchial carcinoma. Angiology 1991;42:985-9.
17. Pierce RJ, Copland JM, Sharpe K, Barter CE. Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality. Am J Respir Crit Care Med 1994;150:947-55.
18. Giordano, Calgagni ML, Meduri G, et al. Perfusion lung scintigraphy for the prediction of postlobectomy residual pulmonary function. Chest 1997;111:1542-7.
19. M Graham MV, Purdy, JA, Emami B, Harms W, Bosch W, Lockett MA, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-9.
20. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001;51:650-9.
21. Pérez CA, Brady LW. Overview. In: Pérez CA, Brady LW, editors. Principles and practice of radiation oncology. Philadelphia: JB Lippincott Company, 1992; p. 1-63.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assoc 1958;55:457-81.
24. Breslow N. A generalized Kruskal-Wallis test for comparing k samples subject to unequal patterns of censorship. Biometrika 1970;57:579-94.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 1966;50:163-70.
26. Cox DR. Regression models and life tables. J Roy Statist Soc 1972;34(series B):187-220.
27. Martini N. Surgical treatment of non-small cell lung cancer by stage. Semin Surg Oncol 1990;6:248-54.
28. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-7.
29. García-Yuste M, Matilla JM, Duque JL, Heras F, Cerezal LJ, Ramos G. Tratamiento quirúrgico del cáncer de pulmón: evaluación comparativa de los sistemas de estadificación de 1986 y 1997. Resultados en 500 pacientes consecutivos. Arch Bronconeumol 2000;36:245-50.
30. Calvo V, Padilla J, París F, Blasco E, Pastor J, García A. Supervivencia posquirúrgica en el estadio II del carcinoma broncogénico no anaplásico de células pequeñas. Arch Bronconeumol 2001;37:19-26.
31. Lederle FA, Niewoehner DE. Lung cancer surgery. A critical review of the evidence. Arch Intern Med 1994;154:2397-400.
32. Morrison R, Deeley TJ, Cleland WP. The treatment of carcinoma of the bronchus: a clinical trial to compare surgery and supervoltage radiotherapy. Lancet 1963;1:683-4.
33. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
34. Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastem Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-64.
35. Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/Il) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:119-30.
36. Albain KS, Crowley JJ, Turrisi AT III, Gandara DR, Farrar WB, Clark JI, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II study, SWOG 9019. J Clin Oncol 2002;20:3454-60.
37. Robert F, Spencer SA, Childs HA, Zhang R, Meredith RF, Wheeler RH, et al. Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer 2002;37:189-99.
38. Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002;53:548-57.
39. Kim TY, Yang SH, Lee SH, Park YS, Im YH, Kang WK, et al. A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol 2002;25:238-43.
40. Aisner J, Hansen HH. Commentary: current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 1986;65:979-86.
41. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001;51:56-61.
42. rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology; 2001, noviembre 4-8; San Francisco. New York: Elsevier, 2001.